{
  "id": 17340198,
  "title": "ani pharmaceuticals svp & cfo Stephen Carey sells $207,679 in stock",
  "url": "https://urgent.news/2026/10/31/ani-pharmaceuticals-svp-cfo-stephen-carey-sells-207-679-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-31T04:31:04.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/ani-pharmaceuticals-svp--cfo-stephen-carey-sells-207679-in-stock-93CH-4989091"
  },
  "original_language": "en",
  "account": "Stephen P. Carey, the SVP and CFO of ANI Pharmaceuticals Inc. (NASDAQ:ANIP), disposed of 2,850 shares of the company's common stock on October 29, 2026. The sale occurred at prices between $72.18 and $73.29, generating a total of $207,679. The transaction was carried out under a pre-approved Rule 10b5-1 trading plan, which Carey established on March 6, 2026. Post-sale, Carey owned 166,143 shares of ANI Pharmaceuticals directly. According to InvestingPro, the company's stock appears undervalued at present, and it has been rated with a strong financial health score. Those interested in a more in-depth analysis can explore one of the seven ProTips provided by the platform or utilize the most undervalued stocks screener.\n\nANI Pharmaceuticals reported better-than-anticipated second-quarter 2026 financials, with adjusted earnings of $2.21 per share, surpassing analysts' expectations of $2.03. The company also experienced record revenue of $266 million, exceeding the forecasted $262.14 million. However, the outlook for Cortrophin Gel, a crucial growth area, has been revised downward. The company scaled back its full-year guidance for Cortrophin from $50 million to $25 million due to weaker-than-expected performance in the first half of the year, despite still projecting 50% to 55% year-over-year growth. Financial analysts Guggenheim maintained a Buy rating on ANI Pharmaceuticals but lowered its price target from $124 to $119, given the earnings report. Similarly, Canaccord Genuity adjusted its price target to $90 from $91, acknowledging the revenue beat but expressing concern over the earnings miss and underwhelming Cortrophin performance. Oppenheimer initiated coverage on the company with a Perform rating and set a price target of $85, emphasizing Cortrophin Gel as an attractive investment opportunity, despite the recent downward adjustment in 2026 guidance. These mixed reactions from analysts highlight a range of opinions regarding ANI Pharmaceuticals' future trajectory.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}